A $336 million fire loss landed in Medline’s latest three-month results. That is nearly nine-tenths of the company’s $395 million in operating income, an unusually large item to find inside a period when gross profit rose 20.3%.

The surface read is straightforward: Medline grew. Revenue increased 4.5% to $7.7 billion for the three months ended June 27, while gross margin widened from 25.0% to 28.8%. The bottom line was less cooperative: operating income fell 6.4%, and diluted EPS dropped from $0.16 to $0.07.

The reason the gross-profit number needs a footnote is tariff refunds. Medline said the refunds helped lift adjusted EBITDA, even as tariffs raised import costs and the company spent more on compensation and benefits tied to headcount investments.

"Medline Brand Segment Adjusted EBITDA for the three months ended June 27, 2026 increased $177 million, or 19.9%, to $1,067 million, compared to $890 million for the respective period in 2025, primarily driven by tariff refunds and growth in net sales, partially offset by higher import costs due to tariffs and higher compensation and benefit expense related to investments in headcount."

Medline, 10-Q filed Aug. 5, 2026

That is a useful map of the quarter. Sales growth and tariff refunds were identified as primary drivers of the adjusted profit improvement. The same sentence also keeps the cost of importing goods and building the workforce in view.

Then the unusual losses arrive below that operating picture.

"The three and six months ended June 27, 2026 also includes loss of $336 million attributable to fire at distribution center in Tracy, California, and $45 million of loss on debt extinguishment and other debt refinancing costs and fees."

Medline, 10-Q filed Aug. 5, 2026

Medline therefore produced more gross profit but less operating income, with the disclosed fire loss and refinancing costs sitting in the same period. Diluted shares also rose 4.4% to 861.0 million, adding another mechanical pressure to EPS.

Cash increased 4.1% to $2.3 billion, while working capital used $324 million, primarily because Medline recorded a $279 million IEEPA tariff refund receivable and $148 million of higher trade receivables tied to sales growth, partly offset by $89 million of customer repayments related to tariff refunds.

That receivable is the bridge between the margin improvement and the cash story. The benefit is visible in earnings, while part of the related cash remains a balance-sheet item. Medline does not say when the refund receivable will convert to cash.

The company’s annual results add a little scale without resolving the quarter’s split personality. Revenue rose 11.5% in 2025 to $28.4 billion, while annual operating margin was 7.8%, above the latest period’s 5.1%. The latest report is not a simple continuation of that annual margin line because it includes the fire loss, refinancing costs, tariff refunds, and higher import costs in one three-month window.

The next number that would sharpen this trade-off is the IEEPA tariff refund receivable balance, alongside customer repayments, in Medline’s next quarterly report. Until then, the latest accounts leave the company with a very specific combination: more sales, a much fatter gross margin, and a fire loss large enough to eat most of operating income.

Medline’s quarter kept tariff refunds, higher import costs, and a $336 million distribution-center fire loss on the same page.